Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant Phase 2/3 in Episodic Migraine
NCT02848326Phase 3Completed
- Sponsor
- Allergan
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine (6 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Mean Monthly Migraine Days at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT02848326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848326.